Mirum Pharmaceuticals Enters Catalyst-Rich Stretch as LIVMARLI Sales and Pipeline Advance
Key takeaways
- LIVMARLI continues to drive Mirum’s commercial momentum, with first-quarter 2026 net sales of $114 million, up 55% year over year.
- Mirum reported encouraging pipeline progress, including positive pivotal data for volixibat in PSC and interim Phase 2b results for brelovitug in hepatitis delta.
- The company remains active in business development, recently adding zilurgisertib for FOP and emphasizing disciplined deal-making in rare diseases.
Mirum Pharmaceuticals Enters Catalyst-Rich Stretch as LIVMARLI Sales and Pipeline Advance Mirum Pharmaceuticals logo Market Beat Wed, May 27, 2026 at 6:09 PM GMT+7 7 min read MIRM Key Points Interested in Mirum Pharmaceuticals, Inc.? Here are five stocks we like better.
LIVMARLI continues to drive Mirum’s commercial momentum, with first-quarter 2026 net sales of $114 million, up 55% year over year. The company raised full-year guidance to $660 million-$680 million, citing strong demand in PFIC and steady growth in Alagille syndrome.
Mirum reported encouraging pipeline progress, including positive pivotal data for volixibat in PSC and interim Phase 2b results for brelovitug in hepatitis delta. The company expects major readouts and regulatory milestones later this year, including an NDA submission for volixibat and full Phase 3 hepatitis delta data.